Alopecia Clinical Trials

84 recruitingLast updated: June 18, 2026

There are 84 actively recruiting alopecia clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Miami, Florida, United States, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Alopecia Trials at a Glance

84 actively recruiting trials for alopecia are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 27 trials, with the heaviest enrollment activity in New York, Miami, and San Antonio. Lead sponsors running alopecia studies include Pfizer, Icahn School of Medicine at Mount Sinai, and Erasmus Medical Center.

Treatments under study

About Alopecia Clinical Trials

Looking for clinical trials for Alopecia? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alopecia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alopecia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 84 trials

Recruiting
Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Alopecia Areata
AbbVie1,500 enrolled271 locationsNCT06012240
Recruiting
Not Applicable

1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Scarring Alopeciaandrogenetic alopecia
Montefiore Medical Center10 enrolled1 locationNCT05460611
Recruiting
Phase 2

Deucravacitinib in the Treatment of Cicatricial Alopecias

Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia
Icahn School of Medicine at Mount Sinai20 enrolled1 locationNCT07508488
Recruiting
Phase 2

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Alopecia Areata
Eli Lilly and Company60 enrolled30 locationsNCT07533006
Recruiting
Phase 2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

Central Centrifugal Cicatricial AlopeciaLichen Planopilaris
Icahn School of Medicine at Mount Sinai30 enrolled1 locationNCT07487948
Recruiting

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

Alopecia Areata
Pfizer850 enrolled58 locationsNCT06531109
Recruiting
Phase 1Phase 2

Study of EPI-001 in Patients With Androgenetic Alopecia

androgenetic alopecia
Epibiotech42 enrolled1 locationNCT07618195
Recruiting
Not Applicable

A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth

Androgenic alopecia
CynosureLutronic44 enrolled2 locationsNCT07588243
Recruiting
Phase 2

A Study of LAD603 in Adults With Alopecia Areata

Alopecia Areata
Almirall, S.A.136 enrolled1 locationNCT07311564
Recruiting
Phase 1Phase 2

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

Androgenetic alopecia (AGA)Healthy Volunteers - Male and Female
Absci Pty Ltd.227 enrolled4 locationsNCT07317544
Recruiting
Phase 3

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

AlopeciaSkin DiseasesAreata Alopecia+3 more
Eli Lilly and Company595 enrolled127 locationsNCT05723198
Recruiting

A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.

Severe Alopecia Areata
Pfizer3,000 enrolled1 locationNCT07152119
Recruiting
Not Applicable

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

Androgenetic alopecia (AGA)
Institute of Dermatology, Thailand80 enrolled2 locationsNCT07536100
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Female Pattern Baldnessandrogenetic alopecia
Industrial Farmacéutica Cantabria, S.A.520 enrolled13 locationsNCT05888922
Recruiting
Not Applicable

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Alopecia
St. Jude Children's Research Hospital40 enrolled1 locationNCT04764357
Recruiting
Not Applicable

JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

Androgenic alopeciaandrogenetic alopecia
Kasr El Aini Hospital25 enrolled1 locationNCT07563036
Recruiting

Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US

Alopecia Areata
Pfizer300 enrolled1 locationNCT07226531
Recruiting
Phase 1

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

HealthySevere Alopecia AreataActive Non-segmental Vitiligo
Innovent Biologics (Suzhou) Co. Ltd.160 enrolled1 locationNCT07554222
Recruiting
Phase 3

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Severe Alopecia Areata
Pfizer140 enrolled41 locationsNCT07029828
Recruiting
Phase 2

PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study

Androgenetic alopecia (AGA)
Nanfang Hospital, Southern Medical University76 enrolled1 locationNCT07335367